Skip to Content
  • Birth of an Idea

    A Little Ambiguity Would Be Welcome Right About Now

    My experimental results came in late Friday afternoon, and. . .well, rarely have I seen less encouraging data. It wasn’t enjoyable. I was there as the numbers for each part of the experiment came through, and I could tell early on that I was in trouble. So, here’s the rundown: the repeat of my previous… Read More
  • Birth of an Idea

    Dr. Lowe? I Have Your Hypothesis on Line Two

    I spoke a couple of weeks ago about my latest series of experiments at work, and I’ve had several inquiries about how things are going. Well, the whole shebang has been in the freezer, actually. The instrument that we need to analyze things (and the person who runs the instrument!) have both been occupied with… Read More
  • Business and Markets

    . . .Your Huddled Pharmas Yearning to Breath Free

    Genetic Engineering News reprints parts of a speech given by Rolf Krebs, chairman of the German drug firm Boehringer Ingleheim, at a recent conference in Hannover. Dr. Krebs was speaking on the differences in pharma research between Europe and America, and he didn’t leave much bottled up: “The framework conditions for the pharmaceutical… Read More
  • Who Discovers and Why

    Weinberg’s “Golden Lessons”

    Nobel laureate Steven Weinberg had a piece back in the Nov. 27 Nature (p. 389) offering advice to people just starting their scientific careers. It’s useful stuff, and the lessons aren’t just for beginners, either. His first of “Four Golden Lessons” is No one knows everything, and you don’t have to. (This came from his… Read More
  • Biological News

    There’d Better Not Be an Argon Receptor

    Signaling between cells is weirder than we used to think it was. There’s a hardy perennial, all right – that sentence could have been written whenever you like for the past fifty years or so. But the surprises keep on coming. Some of the most intense communication needs are between neurons, as you’d expect, and… Read More
  • Biological News

    All Bets Are Now Officially Off

    Remember the genomics gold rush? Back about five or six years ago? Sure you do! People were lining up to throw money at companies that could deliver human gene sequences, as part of the never-ending search for new drug targets. (OK, it’s not quite never-ending, but for the time horizon we have in the industry… Read More
  • Patents and IP

    And Now for Something Completely Different

    Here’s something new to finish off the week. As even casual observers know, patents are extremely important in the drug industry. We spend whacking amounts of time writing them, reading them, and worrying about the ones that other companies have filed. And it should also be clear, to the same laid-back observers, that a good… Read More
  • Drug Prices

    The Pricing Weapon

    I’ve been meaning to get around to the subject of Abbott’s HIV protease inhibitor, Norvir (ritonavir.) Actually, the subject I’ve really need to get around to is its price, which in December went up by about a factor of four. That’s a pretty steep move for something that’s been on the market for seven years… Read More
  • Autism

    Here and There

    I wanted to take a moment to mention some interesting posts around Blogdom that readers may not have seen. In a response to the news on secretin for autism (see my post below), Dwight Meredith writes on what it was like at its peak of interest: Human secretin, swine secretin, herbal secretin (which as far… Read More
  • Birth of an Idea

    If This Doesn’t Work, There’s Only Reality To Fall Back On

    Time for an update on my research, where I’m still working on the odd idea that I’ve been speaking about. In my last installment, I had what seemed to be good results from an experiment, and I was getting ready to set up some more control runs to see if things would behave as they… Read More